Compare PFSA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFSA | BIVI |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.5M |
| IPO Year | N/A | N/A |
| Metric | PFSA | BIVI |
|---|---|---|
| Price | $2.97 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 241.9K | 99.6K |
| Earning Date | 04-02-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 122.22 | N/A |
| 52 Week Low | $2.90 | $1.06 |
| 52 Week High | $957.00 | $19.50 |
| Indicator | PFSA | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 92.02 | 41.89 |
| Support Level | $0.05 | $1.06 |
| Resistance Level | $4.22 | $1.21 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.34 | 0.00 |
| Stochastic Oscillator | 70.34 | 25.00 |
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.